Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan

eJHaem

article

Yurie Miyamoto-Nagai¹  Naoya Mimura¹  Nobuhiro Tsukada³  Nobuyuki Aotsuka⁴  Masaki Ri⁵  Yuna Katsuoka⁶  Toshio Wakayama⁷  Rikio Suzuki⁸  Yoriko Harazaki⁹  Morio Matsumoto^1,10  Kyoya Kumagai^1,11  Takaaki Miyake^1,12  Shuji Ozaki^1,13  Katsuhiro Shono^1,14  Hiroaki Tanaka^1,15  Arika Shimura^1,16  Yoshiaki Kuroda^1,17  Kazutaka Sunami^1,18  Kazuhito Suzuki^1,19  Takeshi Yamashita^2,20  Kazuyuki Shimizu^2,21  Hirokazu Murakami^2,22  Masahiro Abe^2,23  Chiaki Nakaseko^2,24  Emiko Sakaida¹ 

[1] Department of Hematology, Chiba University Hospital;Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital;Division of Hematology, Japanese Red Cross Medical Center;Department of Hematology and Oncology, Japanese Red Cross Narita Hospital;Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences;Department of Hematology, National Hospital Organization Sendai Medical Center;Department of Hematology and Oncology, Shimane Prefectural Central Hospital;Department of Hematology and Oncology, Department of Medicine, Tokai University School of Medicine;Department of Hematology, Miyagi Cancer Center;Department of Hematology, National Hospital Organization Shibukawa Medical Center;Division of Hematology-Oncology, Chiba Cancer Center;Department of Oncology and Hematology, Shimane University Hospital;Department of Hematology, Tokushima Prefectural Central Hospital;Department of Hematology, Chiba Aoba Municipal Hospital;Department of Hematology, Asahi General Hospital;Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo;Department of Hematology, National Hospital Organization Hiroshimanishi Medical Center;Department of Hematology, National Hospital Organization Okayama Medical Center;Department Clinical Oncology and Hematology, The Jikei University Kashiwa Hospital;Department of Internal Medicine, Keiju Kanazawa Hospital;Department of Hematology/Oncology, Higashi Nagoya National Hospital;Faculty of Medical Technology and Clinical Engineering, Gunma University of Health and Welfare;Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School;Department of Hematology, International University of Health and Welfare School of Medicine

关键词: autologous stem cell transplantation;    Multiple myeloma;    peripheral blood stem cells;    poor mobilizers;   

DOI  :  10.1002/jha2.534

来源: Wiley

【 摘 要 】

Autologous stem cell transplantation (ASCT) remains an important therapeutic strategy for multiple myeloma; however, a proportion of patients fail to mobilize a sufficient number of peripheral blood stem cells (PBSCs) to proceed to ASCT. In the present study, we aimed to clarify the characteristics and outcomes of poor mobilizers. Clinical data on poorly mobilized patients who underwent PBSC harvest for almost 10 years were retrospectively collected from 44 institutions in the Japanese Society of Myeloma (JSM). Poor mobilizers were defined as patients with less than 2 × 10 6 /kg of CD34 + cells harvested at the first mobilization. The proportion of poor mobilization was 15.1%. A sufficient dataset including overall survival (OS) was evaluable in 258 poor mobilizers. Overall, 92 out of 258 (35.7%) poor mobilizers did not subsequently undergo ASCT, mainly due to an insufficient number of PBSCs. Median OS from apheresis was longer for poor mobilizers who underwent ASCT than for those who did not (86.0 vs. 61.9 mon., p  = 0.02). OS from the diagnosis of poor mobilizers who underwent ASCT in our cohort was similar to those who underwent ASCT in the JSM database (3y OS rate, 86.8% vs. 85.9%). In this cohort, one-third of poor mobilizers who did not undergo ASCT had relatively poor survival. In contrast, the OS improved in poor mobilizers who underwent ASCT. However, the OS of extremely poor mobilizers was short irrespective of ASCT.

【 授权许可】

Unknown